{
    "nctId": "NCT04619485",
    "briefTitle": "Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy",
    "officialTitle": "Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy: A Randomized, Double-blind, Sham-controlled Trial - LIGHT Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Genitourinary Syndrome of Menopause",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 84,
    "primaryOutcomeMeasure": "Female Sexual Function Index (FSFI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* BC treated with aromatase inhibitors \u00b1 GnRH analogues (aGnRH)\n* Menopause (natural or induced) and signs / symptoms of GSM\n* Vaginal pH \u22655\n* Negative Human Papillomavirus (HPV) cytology and / or determination\n* Intention or willingness to have sex\n* Signed informed consent\n\nExclusion Criteria:\n\n* Vaginal hormonal treatment in the last 6 months\n* Vaginal moisturizers and / or lubricants during the 30 days prior to study treatment\n* Laser treatment, radiofrequency, hyaluronic acid, lipofilling in the vagina during the last 2 years\n* Ospemifene treatment\n* Being affected for: active infection of the genital tract; intraepithelial neoplasm of cervix, vagina, or vulva; have or have been treated for genital cancer\n* Genital prolapse stage \u2265II.",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}